Latest Feature

Podcast: Haemonetics CEO Brian Concannon at MassDevice.com's DeviceTalks

Haemonetics CEO Brian Concannon discusses how the company will transform blood management in the coming years at MassDevice.com's DeviceTalks Boston event.

Calhoun Vision aims to disrupt ophthalmology with its light-adjustable lens

Calhoun Vision CEO Verne Sharma tells MassDevice.com why his company's light-adjustable lens will disrupt the practice of ophthalmology.

Silicon Valley in-depth: Unraveling arrhythmia with iRhythm CEO Kevin King

Kevin King, CEO of Silicon Valley digital health company iRhythm, tells MassDevice about the promise of Big Data and how remote patient monitoring can reveal intricate details of the habits of the heart.

Podcast: Covidien's Enxing Seng talks Medtronic merger, future of medicine at De

Covidien's Stacy Enxing Seng speaks to MassDevice.com about the Medtronic merger during our DeviceTalks Minnesota event.

FDA cybersecurity rejections are on the way

The FDA is ramping up its cybersecurity labs and may start rejecting insecure technologies sooner than you think.

Subscribe to the MassDevice
Newsletter
Enter your email:

Need Medtech news in a minute? We Deliver!


MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

MassDevice.com +3 | The top 3 medtech stories for July 23, 2014

July 23, 2014 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

 

Trice Medical reels in $12M, ex-Embrella founder O'Donnell

July 23, 2014 by Brad Perriello

Trice Medical says it reeled in the 1st tranche of a nearly $12 million Series B round and named ex-Embrella Cardiovascular Jeffrey O'Donnell Sr. as chairman & CEO.

Trice Medical reels in $12M, ex-Embrella founder O'Donnell

Trice Medical said it raised the 1st tranche of an $11.6 million Series B round and named medtech veteran Jeffrey O'Donnell Sr. as its new CEO.

FDA warns CareFusion over modified devices, quality control

July 23, 2014 by Brad Perriello

The FDA wants CareFusion to stop selling its anesthesia breathing circuit and the Denver ascites shunt and percutaneous access kit until it applies for clearance for changes made to the devices and clears up some quality control issues at a plant in Illinois.

FDA warns CareFusion over modified devices, quality control

GPO: Teleflex deepens surgical partnership with Amerinet

July 23, 2014 by Arezu Sarvestani

Teleflex plans to offer its surgical devices at exclusive rates to Amerinet members in a new agreement between the healthcare companies.

Teleflex deepends surgical partnership with Amerinet

Technology giant Teleflex (NYSE:TFX) announced this week that it signed a new agreement to provide its surgical devices at special rates to members of Amerinet.

Occlutech claims another win over St. Jude Medical

July 23, 2014 by Brad Perriello

Occlutech says a U.K. court invalidated a patent held by St. Jude Medical covering atrial septal occluder technology.

Occlutech claims another win over St. Jude Medical

DARPA taps NeuroPace for memory loss trial

July 23, 2014 by Arezu Sarvestani

NeuroPace teams up with the Defense Advanced Research Projects Agency to examine use of implanted neurostimulators to help restore memory.

DARPA taps NeuroPace for memory loss trial

Epilepsy treatment devices maker NeuroPace hopes to expand its clinical applications by supporting a research initiative to evaluate neurostimulation implants in treatment of memory deficits.

Ulthera pulls $86M IPO in favor of $600M merger

July 23, 2014 by Arezu Sarvestani

Aesthetics devices maker Ulthera withdraws its $86 million initial public offering after agreeing to an acquisition by Merz that's valued at up to $600 million.

Ulthera pulls IPO in favor of merger

Arizona device maker Ulthera is ditching its planned initial public offering in favor of a $600 million merger with larger aesthetics company Merz Inc., according to an SEC filing.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp